Cargando…

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer

The CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) plays an extremely important role of the programed death receptor ligand-1 (PD-L1) protein. Our study is aimed at investigating the expression of CMTM6 and PD-L1 proteins in triple-negative breast cancer and their correlation with the cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Shuai, Ma, Hong-Yan, Sang, Yin-zhou, Ju, Ying-Bo, Liu, Xiao-Yun, Zhang, Zhi-Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283057/ https://www.ncbi.nlm.nih.gov/pubmed/35845949 http://dx.doi.org/10.1155/2022/8118909

Ejemplares similares

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer
por: Tian, Yiping, et al.
Publicado: (2021)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
por: Li, Xin, et al.
Publicado: (2020)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape
por: Dong, Li-Feng, et al.
Publicado: (2023)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
por: Gao, Feng, et al.
Publicado: (2019)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer
por: Zhang, Chao, et al.
Publicado: (2021)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

MicroRNA-582-5p promotes triple-negative breast cancer invasion and metastasis by antagonizing CMTM8
por: Zeng, Xue, et al.
Publicado: (2021)

CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
por: Zeisbrich, Markus, et al.
Publicado: (2021)

CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma
por: Yugawa, Kyohei, et al.
Publicado: (2020)

HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer
por: Liu, Yanbin, et al.
Publicado: (2021)

Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
por: Long, Yiru, et al.
Publicado: (2023)

CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer
por: Wu, Xuehui, et al.
Publicado: (2021)

Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances
por: Chen, Zhi, et al.
Publicado: (2021)

Clinical significance of CMTM4 expression in hepatocellular carcinoma
por: Bei, Chunhua, et al.
Publicado: (2017)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
por: Song, Xin, et al.
Publicado: (2021)

Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma
por: Wang, Ziqi, et al.
Publicado: (2021)

Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2021)

Expression of CMTM4 shows clinical significance in lung cancer
por: Zhu, Xiaonian, et al.
Publicado: (2020)

Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma
por: Tan, Shengkui, et al.
Publicado: (2022)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
por: Tashireva, Liubov A., et al.
Publicado: (2023)

PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
por: Alkaabi, Duaa, et al.
Publicado: (2023)

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer
por: Yin, Bo, et al.
Publicado: (2022)

Circular RNA hsa_circ_0067842 facilitates tumor metastasis and immune escape in breast cancer through HuR/CMTM6/PD-L1 axis
por: Li, Juan, et al.
Publicado: (2023)

The risk of PD-L1 expression misclassification in triple-negative breast cancer
por: Ben Dori, Shani, et al.
Publicado: (2022)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
por: Xing, Fei, et al.
Publicado: (2023)

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment
por: Zhao, Yanbin, et al.
Publicado: (2021)

Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‐L1
por: Chui, Noreen Nog‐Qin, et al.
Publicado: (2021)

Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
por: Dobritoiu, Florin, et al.
Publicado: (2022)

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
por: Barrett, Michael T., et al.
Publicado: (2018)

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
por: Chen, Xingyu, et al.
Publicado: (2022)

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
por: Tang, Yuxia, et al.
Publicado: (2022)

Prognostic Significance of CCNB2 Expression in Triple-Negative Breast Cancer
por: Cao, Jintao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mtgra84u4sdfntgd6theeiin74